Back to results
US 2014/0227302 A1Published application
Gamma secretase inhibitors
AssigneeMerck Sharp & Dohme Corp.
InventorsWen-Lian Wu, Duane A. Burnett
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compounds of Formula (I) (I) and pharmaceutically acceptable salts thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and use of the compound in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease.
Claims20
A compound of Formula (I)
- or a pharmaceutically acceptable salt thereof, wherein
- R is a 5-6 membered heteroaryl containing 1-2 nitrogen atoms optionally substituted with one L1 group;
- or a —(C1-C6)alkyl(5-6 membered)heteroaryl containing 1-3 heteroatoms selected from N and O optionally substituted with one L1 group, with the proviso that the (5-6 membered)heteroaryl of the —(C1-C2)alkyl(5-6 membered)heteroaryl is not furanyl;
- R1 is independently selected from the group consisting halogen, (C1-C6)alkyl, —CN, —CF3, —O—(C1-C6)alkyl, —O-(halo(C1-C6)alkyl), —C(O)—O—(C1-C6)-OH-substituted (C1-C4)alkyl, halo(C1-C6)alkyl, —(C1-C4)alkoxy-OH, —(C1-C4)alkoxy(C1-C4)alkoxy and —S(O)2(C1-C6)alkyl;
- n is 0, 1, 2, or 3;
- Ar is selected from the group consisting of phenyl optionally substituted with 1 or 2 L2 groups, and pyridyl optionally substituted with 1 or 2 L2 groups;
- L1 is independently selected from the group consisting of —OCH3, —NH2, ═O, and (C1-C5)alkyl;
- and
- L2 is independently selected from the group consisting of halogen, (C1-C6)alkyl, —CN, —CF3, —O—(C1-C6)alkyl, —O-(halo(C1-C6)alkyl), —C(O)—O—(C1-C6)alkyl, —OH— substituted (C1-C6)alkyl, halo(C1-C6)alkyl, —OH-substituted (C1-C4)alkoxy, —(C1-C4)alkoxy(C1-C4)alkoxy and —S(O)2(C1-C6)alkyl.
6 more elements
Dependencies are inferred from the claim text.